ACT is solution-minded and result-driven.
After the Supreme Court overturned Roe v. Wade in 2022, we got to work advocating for and passing state-level legislation that shields clinicians licensed in states where abortion remains legal from criminal or civil liability. With laws on the books in states like NY, WA, CO, VT, MA, and CA, we established a playbook for shielded clinicians to provide safe, timely, and affordable medication abortion via telemedicine to patients in states where abortion is banned or restricted.
We’re now focused on working directly with clinicians to launch shielded practices so more patients can legally receive interstate telemedicine abortion care.
WHY TELEMEDICINE ABORTION?
For more than two decades, since it was approved by the U.S. Food and Drug Administration (FDA), medication abortion has been a safe, timely, and evidence-based treatment for patients across the globe. Telemedicine abortion offers greater freedom for everyone to make their own reproductive health decisions and is now the most common form of abortion in the U.S. The two-step process of mifepristone and misoprostol is an FDA-approved method for terminating early pregnancies up to 12 weeks and can be done in the comfort of a patient’s home with the support of a telemedicine provider. Access to medication abortion via telehealth is also critical for treating the communities most impacted by abortion bans and restrictions, particularly BIPOC, LGBTQ+, low-income, dis/abled, and rural patients – many of whom experience higher maternal mortality rates and significant barriers to care.
We understand that starting a shielded practice may seem complex and
overwhelming, especially in such an uncertain political climate. That’s why ACT is
committed to providing clinicians with the medical, legal, and technical resources and
assistance they need to begin treating patients across state lines, including:
o Malpractice insurance
o pLLC or PC business registration
o Data security
o Dispensing software
o Pharmaceutical distributor contracts
o Mifepristone and misoprostol distributor contracts
o Mail-order pharmacy agreements